May 7, 2007
Preliminary Results Presented at the 2007 American Transplant Congress
CTI Clinical Trial and Consulting Services (CTI) announced the completion of patient enrollment in a Phase II clinical trial of YSPSL for prevention of delayed graft function (DGF) in kidney transplant patients. YSPSL is a recombinant molecule resulting from the fusion of Pselectin glycoprotein ligand (PSGL) and human IgG1.
CTI is managing the clinical trial program on behalf of Y’s Therapeutics. The clinical trial enrolled 75 patients across 15 leading US transplant centers to evaluate the safety and efficacy of YSPSL (r-PSGL-Ig, recombinant P-selectin glycoprotein immunoglobulin) for prevention of DGF in patients undergoing cadaveric kidney transplantation.
The results of the first portion of the study were given as an oral presentation during the 2007 American Transplant Congress being held in San Francisco, CA. The paper, entitled “YSPSL (rPSGL-Ig) for the Prevention of Delayed Graft Function (DGF): Preliminary Results of Ongoing Dose Escalation and Efficacy Study” was presented during the “Kidney Immunosuppression: Newest Agents” session, beginning at 4:00pm on Sunday, May 6, 2007.
“We would like to thank the investigators and clinical sites for their efforts in recruiting and enrolling patients into this complex clinical trial and we would like to thank Y’s Therapeutics for entrusting the management of this important trial to us,” said Timothy J Schroeder, President and CEO of CTI Clinical Trial and Consulting Services.
The results from the Phase II clinical trial, including the placebo-controlled, blinded portion of the study, will be available after analysis of the six-month follow-up data of all enrolled patients in the study.